Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Steroidal pure antioestrogens.

A E Wakeling, J Bowler

    The Journal of Endocrinology
    |March 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    ICI 164,384, a novel oestrogen analogue, acts as a pure antagonist, blocking oestrogen and tamoxifen effects on the uterus. It shows high affinity for the oestrogen receptor and inhibits cell growth, indicating a pure anti-oestrogenic action.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Metal hypersensitivity in total joint replacement: review of the literature and practical guidelines for evaluating prospective recipients.

    Orthopedics·2014
    Same author

    The reversible cerebral vasoconstriction syndrome in association with venlafaxine and methenamine.

    BMJ case reports·2013
    Same author

    Birth of a biome: insights into the assembly and maintenance of the Australian arid zone biota.

    Molecular ecology·2008
    Same author

    Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment.

    Endocrine-related cancer·2005
    Same author

    Inhibitors of growth factor signalling.

    Endocrine-related cancer·2005
    Same author

    Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.

    Endocrine-related cancer·2004

    Area of Science:

    • Endocrinology
    • Pharmacology
    • Molecular Biology

    Background:

    • Oestrogen receptor (ER) modulators are crucial in reproductive health and cancer therapy.
    • Novel compounds are needed to selectively target ER pathways.
    • Understanding oestrogen action requires potent and specific antagonists.

    Purpose of the Study:

    • To evaluate the uterine effects of novel 7 alpha-alkyl amide analogues of oestradiol.
    • To characterize the activity of compound ICI 164,384 as an oestrogen antagonist.
    • To determine the binding affinity and in vitro efficacy of ICI 164,384.

    Main Methods:

    • Measurement of uterine effects in rats and mice.
    • Assessment of oestrogenic and anti-oestrogenic activity in vivo.

    Related Experiment Videos

  • Determination of oestrogen receptor binding affinity.
  • In vitro inhibition of oestradiol-induced cell growth (ZR-71-1 cells).

    • Main Results:

    • ICI 164,384 demonstrated no oestrogenic activity in rat and mouse uteri.
    • ICI 164,384 completely blocked the uterine stimulatory effects of oestradiol and tamoxifen.
    • Biological activity was restricted to the 7 alpha-isomers.
    • ICI 164,384 exhibited significantly higher affinity for the rat uterus oestrogen receptor than tamoxifen.
    • ICI 164,384 dose-dependently inhibited oestradiol-induced ZR-71-1 cell growth in vitro.

    Conclusions:

    • ICI 164,384 functions as a pure antagonist of oestrogen action.
    • The compound's high receptor affinity and potent antagonistic effects support its potential therapeutic applications.
    • Novel 7 alpha-alkyl amide analogues represent a promising class of selective oestrogen receptor modulators.